Lifecore Biomedical, Inc. Announces Agreement with Hyalose to Distribute Hyalose's Nano HA(TM), Oligo HA(TM), and Select HA(TM)

CHASKA, Minn.--(BUSINESS WIRE)--LIFECORE BIOMEDICAL, LLC announced today that it has entered into a distribution agreement to market Hyalose L.L.C.’s line of hyaluronan research tools – Oligo-HA™, NanoHA™, Select HA™, Biotinylated Select HA™, and Hyalose Ladders. “Lifecore is pleased to be able to offer an expanded line of hyaluronan based biomaterials to the academic and corporate research communities through this distribution agreement, which nicely complements Lifecore’s offering of a broad range of molecular weights of pharmaceutical grade hyaluronan.”, said Dr. Kipling Thacker, VP of New Business Development for Lifecore. John Hoopingarner, President of Hyalose, added “This non-exclusive distribution agreement will now provide our hyaluronan to a broader research community of biologists, tissue and material engineers.”